Flared ribs on GLP-1s: real side effect or TikTok myth?
Quick answer
The creator is four months into tirzepatide 7.5mg (Zepbound) and reporting steady weekly weight loss with fluctuating appetite that appears cycle-linked. Their observation of rib flare is likely a body composition perception shift as subcutaneous fat decreases, not a medication side effect or structural injury. Their concern about the auto-injector bead is a device-use question that Eli Lilly addresses in Zepbound patient instructions.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @eulee123 actually say?
This is mostly a personal update video, not a health claims video. The creator, four months into 7.5mg tirzepatide (Zepbound), reported losing 1.8 pounds in one week during their period, noted increased hunger the prior week that they attributed to their menstrual cycle, and spent a good chunk of the video asking whether "flared ribs" are a real anatomical concept or "just a made up concept." They also flagged anxiety about a bead of medication appearing on the auto-injector tip after opening it.
To be clear: they are not claiming flared ribs are caused by GLP-1 drugs. They are noticing their body differently as they lose weight and asking their audience what they're looking at. That distinction matters for how we evaluate this video.
Does the science back this up?
Flared ribs, technically called "rib flare" or "costal flare," are a real anatomical variation. They are not made up. The term refers to the lower ribs, particularly ribs 10 through 12, angling outward more than typical, making the lower rib cage visibly protrude. It is commonly discussed in physiotherapy literature in the context of breathing mechanics and core pressure management.
Research on thoracic morphology, including work by Lee and colleagues (2019, Journal of Physical Therapy Science), describes how anterior rib flare can be associated with altered diaphragm positioning and reduced intra-abdominal pressure control. It is not a disease. It is not dangerous on its own. It becomes clinically relevant when it correlates with breathing dysfunction or pelvic floor issues, particularly postpartum. The creator's instinct that it "feels real" is correct. It is a real structural pattern that many people simply notice more as body fat decreases and the rib cage becomes more visible.
What did they get wrong (or right)?
They got the basic intuition right: rib flare is a real thing, not a social media invention. Credit where it's due.
What they got slightly muddled is the idea that one side feeling "weirder" than the other is necessarily a sign of a problem. Asymmetry in rib positioning is common and usually benign. A 2020 review in the British Journal of Sports Medicine (Beales et al.) noted that thoracic asymmetry is a near-universal finding and correlates poorly with symptoms or functional limitation in asymptomatic individuals. The creator is understandably more aware of their body shape as they lose weight, which is a normal psychological response to body change. But self-diagnosing structural problems from TikTok comments is not a substitute for a physiotherapy assessment if there is actual pain or breathing difficulty.
Their hunger attribution to the menstrual cycle is also plausible. Estrogen and progesterone shifts in the luteal phase do influence appetite signaling, and there is reasonable evidence (Dye and Blundell, 1997, Physiology and Behavior) that caloric intake increases in the late luteal phase.
What should you actually know?
A few things are worth addressing directly for anyone on a GLP-1 medication having similar questions.
- Rib flare becomes more visible with fat loss. As subcutaneous fat around the torso decreases, structural features of the skeleton that were previously obscured become apparent. This is not a side effect of tirzepatide. It is geometry.
- The medication bead anxiety is worth addressing. A small droplet at the auto-injector tip after removing the cap is a known occurrence with prefilled injection devices. Eli Lilly's Zepbound instructions note that a small drop at the needle tip is normal and does not mean the dose is lost. If the bead is large or the device has been compromised, patients should contact their pharmacy, not inject.
- Staying on 7.5mg because appetite is returning is a clinical decision, not a content decision. The creator's reasoning, that the hunger was cycle-related and not medication failure, is reasonable but should be discussed with a prescriber, not decided based on a TikTok theory.
- GLP-1 medications do not treat rib flare. Stating this plainly because the hashtag context could imply a connection where none exists.
Bottom line
This video is low on medical claims and high on relatable body-awareness anxiety. The creator is asking honest questions about something they're noticing, which is rib flare, and their instinct that it's real is correct. The video does not spread misinformation. It does reflect how weight loss changes the relationship people have with their bodies in ways that can feel disorienting, and that deserves a straight answer rather than dismissal.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Flared ribs on GLP-1s: real side effect or TikTok myth?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Claim verdict
The useful answer behind this video
Claim being checked
The creator is four months into tirzepatide 7.
FormBlends verdict
The creator is four months into tirzepatide 7.5mg (Zepbound) and reporting steady weekly weight loss with fluctuating appetite that appears cycle-linked. Their observation of rib flare is likely a body composition perception shift as subcutaneous fat decreases, not a medication side effect or structural injury. Their concern about the auto-injector bead is a device-use question that Eli Lilly addresses in Zepbound patient instructions.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is four months into tirzepatide 7.5mg (Zepbound) and reporting steady weekly weight loss with fluctuating appetite that appears cycle-linked. Their observation of rib flare is likely a body composition perception shift as subcutaneous fat decreases, not a medication side effect or structural injury. Their concern about the auto-injector bead is a device-use question that Eli Lilly addresses in Zepbound patient instructions.
- Rib flare is a real anatomical variation involving outward angulation of the lower ribs, not a social media invention or a GLP-1 side effect.
- Fat loss can make skeletal features like the lower rib cage more visible, which is a geometry change, not a medical complication of tirzepatide.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Rib flare is a real anatomical variation involving outward angulation of the lower ribs, not a social media invention or a GLP-1 side effect.
- Fat loss can make skeletal features like the lower rib cage more visible, which is a geometry change, not a medical complication of tirzepatide.
- Luteal phase (pre-period) appetite increases are documented: Dye and Blundell (1997) found measurable caloric intake rises in the days before menstruation, consistent with the creator's experience.
- Thoracic asymmetry is near-universal in asymptomatic adults and correlates poorly with pain or dysfunction (Beales et al., 2020, British Journal of Sports Medicine).
- A small medication droplet at a Zepbound auto-injector tip after cap removal is addressed in Eli Lilly patient instructions as normal and does not mean the dose is incomplete.
- Decisions about staying on a dose due to returning appetite should involve a prescriber, not just a content-based inference, even if the reasoning is plausible.
- This video makes no false medical claims. Its primary value is normalizing the body-awareness anxiety that accompanies significant weight loss.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
eun 🤸 · TikTok creator
19.5K views on this video
flared ribs feel simultaneously so made up but also so real #glp1 #zepbound
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by eun 🤸, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.